Recap of Today’s Hot Plays & A Glimpse at Tomorrow’s Hot Stocks To Watch


 
 
06:55 10/17/2017

The Dow shattered the 23,000 mark today but closed below it. Here are some of today’s plays worth getting on your watch list tomorrow.



AmpliPhi Biosciences Corporation APHB  – Traded ten times its average volume to close up 26% at $1.52 with strong after hours action printing $1.70 highs. We have this on watch for continuation tomorrow given they have a conference call at 2 PM EST. APHB is a biotechnology company that focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections.



TransEnterix, Inc. TRXC  – Still on the radar for one more push tomorrow after an impressive session today with heavy volume. Closed up after hours and will be buzzing overnight to entice more bulls for tomorrows session. TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options.



Social Reality, Inc. SRAX  – Great push today on news they are going to pursue strategic alternatives for SRAXmd healthcare business despite closing down after hours. Social Reality, Inc., an Internet advertising and platform technology company, provides tools to automate the digital advertising market in the United States. Its technology tools enable publishers and advertisers to maximize their digital advertising initiatives.



Neothetics, Inc.NEOT  – Closed up after hours after a record volume day. Shares rallied on heavy volume after news on merger agreement with Evofem Biosciences Inc. The merger will position the combined company with an opportunity to become a leading women’s health company that develops and commercializes novel products. Upon closing of the transaction, Neothetics will be renamed Evofem Biosciences, Inc., and will be under the leadership of Evofem Biosciences’ Chief Executive Officer, Saundra Pelletier. Neothetics, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutics for the aesthetic market. Its lead product candidate is LIPO-202, an injectable formulation of salmeterol xinafoate for the reduction of localized fat deposits under the chin, or submental fat, as well as for reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.


This article has been provided by a Chasing Markets contributor. All content submitted by this author represent their personal opinions, and should be considered as such for entertainment purpose only. All opinions expressed are those of the writer, and may not necessarily represent fact, opinions, or bias of Chasing Markets.
Most Read